-
2
-
-
23044436187
-
Malignant mesothelioma
-
DOI 10.1016/S0140-6736(05)67025-0, PII S0140673605670250
-
Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408. (Pubitemid 41073959)
-
(2005)
Lancet
, vol.366
, Issue.9483
, pp. 397-408
-
-
Robinson, B.W.S.1
Musk, A.W.2
Lake, R.A.3
-
3
-
-
0041629528
-
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
-
DOI 10.1200/JCO.2003.11.136
-
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44. (Pubitemid 46606305)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.14
, pp. 2636-2644
-
-
Vogelzang, N.J.1
Rusthoven, J.J.2
Symanowski, J.3
Denham, C.4
Kaukel, E.5
Ruffie, P.6
Gatzemeier, U.7
Boyer, M.8
Emri, S.9
Manegold, C.10
Niyikiza, C.11
Paoletti, P.12
-
4
-
-
0032952875
-
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
-
discussion 63-5
-
Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63; discussion 63-5.
-
(1999)
J Thorac Cardiovasc Surg
, vol.117
, pp. 54-63
-
-
Sugarbaker, D.J.1
Flores, R.M.2
Jaklitsch, M.T.3
Richards, W.G.4
Strauss, G.M.5
Corson, J.M.6
-
5
-
-
4644362833
-
Pleural mesothelioma: Little evidence, still time to do trials
-
DOI 10.1016/S0140-6736(04)17108-0, PII S0140673604171080
-
Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet 2004;364:1183-5. (Pubitemid 39296609)
-
(2004)
Lancet
, vol.364
, Issue.9440
, pp. 1183-1185
-
-
Treasure, P.T.1
Sedrakyan, A.2
-
6
-
-
68349110548
-
Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia
-
Hasani A, Alvarez JM, Wyatt JM, Bydder S, Millward M, Byrne M, et al. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol 2009;4: 1010-6.
-
(2009)
J Thorac Oncol
, vol.4
, pp. 1010-1016
-
-
Hasani, A.1
Alvarez, J.M.2
Wyatt, J.M.3
Bydder, S.4
Millward, M.5
Byrne, M.6
-
7
-
-
0347087214
-
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma
-
DOI 10.1016/S0169-5002(03)00292-7
-
van Klaveren RJ, Aerts JG, de Bruin H, Giaccone G, Manegold C, van Meerbeeck JP. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 2004;43:63-9. (Pubitemid 38096293)
-
(2004)
Lung Cancer
, vol.43
, Issue.1
, pp. 63-69
-
-
Van Klaveren, R.J.1
Aerts, J.G.J.V.2
De Bruin, H.3
Giaccone, G.4
Manegold, C.5
Van Meerbeeck, J.P.6
-
8
-
-
0346456852
-
Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: Report of four cases
-
DOI 10.1016/j.lungcan.2003.07.005
-
Monetti F, Casanova S, Grasso A, Cafferata MA, Ardizzoni A, Neumaier CE. Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases. Lung Cancer 2004;43:71-4. (Pubitemid 38096294)
-
(2004)
Lung Cancer
, vol.43
, Issue.1
, pp. 71-74
-
-
Monetti, F.1
Casanova, S.2
Grasso, A.3
Cafferata, M.A.4
Ardizzoni, A.5
Neumaier, C.E.6
-
9
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
-
10
-
-
1342267614
-
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
-
DOI 10.1093/annonc/mdh059
-
Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15: 257-60. (Pubitemid 38262625)
-
(2004)
Annals of Oncology
, vol.15
, Issue.2
, pp. 257-260
-
-
Byrne, M.J.1
Nowak, A.K.2
-
11
-
-
33646949799
-
Variability in mesothelioma tumor response classification
-
DOI 10.2214/AJR.05.0076
-
Armato SG III, Ogarek JL, Starkey A, Vogelzang NJ, Kindler HL, Kocherginsky M, et al. Variability in mesothelioma tumor response classification. AJR Am J Roentgenol 2006;186:1000-6. (Pubitemid 46100199)
-
(2006)
American Journal of Roentgenology
, vol.186
, Issue.4
, pp. 1000-1006
-
-
Armato III, S.G.1
Ogarek, J.L.2
Starkey, A.3
Vogelzang, N.J.4
Kindler, H.L.5
Kocherginsky, M.6
MacMahon, H.7
-
12
-
-
33645974029
-
Modeling of mesothelioma growth demonstrates weaknesses of current response criteria
-
Oxnard GR, Armato SG III, Kindler HL. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer 2006;52:141-8.
-
(2006)
Lung Cancer
, vol.52
, pp. 141-148
-
-
Oxnard, G.R.1
Armato III, S.G.2
Kindler, H.L.3
-
13
-
-
34548552737
-
18F-FDG PET scans
-
DOI 10.2967/jnumed.107.042333
-
Francis RJ, Byrne MJ, Van Der Schaaf AA, Boucek JA, Nowak AK, Phillips M, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007;48:1449-58. (Pubitemid 47397395)
-
(2007)
Journal of Nuclear Medicine
, vol.48
, Issue.9
, pp. 1449-1458
-
-
Francis, R.J.1
Byrne, M.J.2
Van Der, S.A.A.3
Boucek, J.A.4
Nowak, A.K.5
Phillips, M.6
Price, R.7
Patrikeos, A.P.8
Musk, A.W.9
Millward, M.J.10
-
14
-
-
33750590454
-
18F]fluorodeoxyglucose
-
DOI 10.1200/JCO.2006.06.8999
-
Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol 2006;24:4587-93. (Pubitemid 46630956)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.28
, pp. 4587-4593
-
-
Ceresoli, G.L.1
Chiti, A.2
Zucali, P.A.3
Rodari, M.4
Lutman, R.F.5
Salamina, S.6
Incarbone, M.7
Alloisio, M.8
Santoro, A.9
-
15
-
-
77951017506
-
A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters
-
Nowak AK, Francis RJ, Phillips MJ, Millward MJ, Van Der Schaaf AA, Boucek J, et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res 2010;16:2409-17.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 2409-2417
-
-
Nowak, A.K.1
Francis, R.J.2
Phillips, M.J.3
Millward, M.J.4
Van Der Schaaf, A.A.5
Boucek, J.6
-
16
-
-
2942722294
-
Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis
-
DOI 10.1378/chest.125.6.2356
-
Kwek BH, Aquino SL, Fischman AJ. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest 2004;125: 2356-60. (Pubitemid 38788210)
-
(2004)
Chest
, vol.125
, Issue.6
, pp. 2356-2360
-
-
Kwek, B.H.1
Aquino, S.L.2
Fischman, A.J.3
-
17
-
-
0029685127
-
Management of recurrent colorectal cancer: Another look at carcinoembryonic antigen-detected recurrence
-
Vauthey JN, Dudrick PS, Lind DS, Copeland EM III. Management of recurrent colorectal cancer: another look at carcinoembryonic antigen-detected recurrence. Dig Dis 1996;14:5-13. (Pubitemid 126478229)
-
(1996)
Digestive Diseases
, vol.14
, Issue.1
, pp. 5-13
-
-
Vauthey, J.N.1
Dudrick, P.S.2
Lind, D.S.3
Copeland III, E.M.4
-
18
-
-
3042598857
-
Clinical utility of cytokeratins as tumor markers
-
DOI 10.1016/j.clinbiochem.2004.05.009, PII S0009912004001316
-
Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004;37:529-40. (Pubitemid 38845016)
-
(2004)
Clinical Biochemistry
, vol.37
, Issue.7
, pp. 529-540
-
-
Barak, V.1
Goike, H.2
Panaretakis, K.W.3
Einarsson, R.4
-
19
-
-
0032425863
-
CA 125: The past and the future
-
Bast RC Jr., Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers 1998;13:179-87. (Pubitemid 29178546)
-
(1998)
International Journal of Biological Markers
, vol.13
, Issue.4
, pp. 179-187
-
-
Bast Jr., R.C.1
Xu, F.-J.2
Yu, Y.-H.3
Barnhill, S.4
Zhang, Z.5
Mills, G.B.6
-
20
-
-
0025939625
-
Clinical applications of serum tumor markers
-
Bates SE. Clinical applications of serum tumor markers. Ann Intern Med 1991;115:623-38.
-
(1991)
Ann Intern Med
, vol.115
, pp. 623-638
-
-
Bates, S.E.1
-
21
-
-
13844289439
-
Screening for colorectal cancer - Now and the near future
-
DOI 10.1053/j.seminoncol.2004.09.031
-
Bromer MQ, Weinberg DS. Screening for colorectal cancer-now and the near future. Semin Oncol 2005;32:3-10. (Pubitemid 40250121)
-
(2005)
Seminars in Oncology
, vol.32
, Issue.1 SPEC. ISS
, pp. 3-10
-
-
Bromer, M.Q.1
Weinberg, D.S.2
-
22
-
-
34247881741
-
Prostate cancer: Epidemiology, screening, and biomarkers
-
Chodak G. Prostate cancer: epidemiology, screening, and biomarkers. Rev Urol 2006;8Suppl 2:S3-8.
-
(2006)
Rev Urol
, vol.8
, Issue.SUPPL. 2
-
-
Chodak, G.1
-
23
-
-
0030069718
-
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers
-
DOI 10.1073/pnas.93.1.136
-
Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40. (Pubitemid 26041483)
-
(1996)
Proceedings of the National Academy of Sciences of the United States of America
, vol.93
, Issue.1
, pp. 136-140
-
-
Chang, K.1
Pastan, I.2
-
24
-
-
0344851540
-
Mesothelin-family proteins and diagnosis of mesothelioma
-
DOI 10.1016/S0140-6736(03)14794-0
-
Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6. (Pubitemid 37443528)
-
(2003)
Lancet
, vol.362
, Issue.9396
, pp. 1612-1616
-
-
Robinson, B.W.S.1
Creaney, J.2
Lake, R.3
Nowak, A.4
Musk, A.W.5
De Klerk, N.6
Winzell, P.7
Hellstrom, K.E.8
Hellstrom, I.9
-
25
-
-
37249061157
-
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions
-
discussion 72
-
Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008;85:265-72; discussion 72.
-
(2008)
Ann Thorac Surg
, vol.85
, pp. 265-272
-
-
Pass, H.I.1
Wali, A.2
Tang, N.3
Ivanova, A.4
Ivanov, S.5
Harbut, M.6
-
26
-
-
77954738635
-
Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma
-
Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, et al. Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010;28:3316-22.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3316-3322
-
-
Wheatley-Price, P.1
Yang, B.2
Patsios, D.3
Patel, D.4
Ma, C.5
Xu, W.6
-
27
-
-
65649133121
-
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment
-
Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, et al. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med 2009;179: 950-4.
-
(2009)
Am J Respir Crit Care Med
, vol.179
, pp. 950-954
-
-
Grigoriu, B.D.1
Chahine, B.2
Vachani, A.3
Gey, T.4
Conti, M.5
Sterman, D.H.6
-
29
-
-
51849148011
-
Assessment of tumour response with (18)F-fluorodeoxyglucose positron emission tomography using three-dimensional measures compared to SUVmax-a phantom study
-
Boucek JA, Francis RJ, Jones CG, Khan N, Turlach BA, Green AJ. Assessment of tumour response with (18)F-fluorodeoxyglucose positron emission tomography using three-dimensional measures compared to SUVmax-a phantom study. Phys Med Biol 2008;53:4213-30.
-
(2008)
Phys Med Biol
, vol.53
, pp. 4213-4230
-
-
Boucek, J.A.1
Francis, R.J.2
Jones, C.G.3
Khan, N.4
Turlach, B.A.5
Green, A.J.6
-
30
-
-
55349134617
-
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers
-
Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79.
-
(2008)
Clin Chem
, vol.54
-
-
Sturgeon, C.M.1
Duffy, M.J.2
Stenman, U.H.3
Lilja, H.4
Brunner, N.5
Chan, D.W.6
-
31
-
-
34548822434
-
Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer
-
DOI 10.1158/1078-0432.CCR-07-0629
-
Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007;13:5076-81. (Pubitemid 47502073)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.17
, pp. 5076-5081
-
-
Cristaudo, A.1
Foddis, R.2
Vivaldi, A.3
Guglielmi, G.4
Dipalma, N.5
Filiberti, R.6
Neri, M.7
Ceppi, M.8
Paganuzzi, M.9
Ivaldi, G.P.10
Mencoboni, M.11
Canessa, P.A.12
Ambrosino, N.13
Chella, A.14
Mutti, L.15
Puntoni, R.16
-
32
-
-
34249781709
-
Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment
-
DOI 10.1158/1078-0432.CCR-06-2144
-
Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007;13:2928-35. (Pubitemid 46850705)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.10
, pp. 2928-2935
-
-
Grigoriu, B.-D.1
Scherpereel, A.2
Devos, P.3
Chahine, B.4
Letourneux, M.5
Lebailly, P.6
Gregoire, M.7
Porte, H.8
Copin, M.-C.9
Lassalle, P.10
|